AC Immune (ACIU) Receivables (2015 - 2024)
AC Immune (ACIU) reported Receivables of $1.3 million for Q4 2024, down 99.99% year-over-year from $17.4 billion in Q1 2024, and down 95.71% on a QoQ basis from $29.4 million in Q3 2024.
AC Immune (ACIU) has 5 years of Receivables data on file, last reported at $1.3 million in Q4 2024.
- Quarterly Receivables fell 99.99% year-over-year to $1.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.3 million (down 99.99% YoY) and the FY2024 annual result came in at $1.3 million, down 99.99% from the prior year.
- Receivables eased to $1.3 million in Q4 2024 per ACIU's latest filing, from $29.4 million in the prior quarter.
- Across five years, Receivables topped out at $17.4 billion in Q4 2023 and bottomed at $1.3 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 29.40 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Dec 31, 2023 | 16.69 Bn |
| Sep 30, 2019 | 3.10 Mn |
| Jun 30, 2019 | 1,143.91 |
| Mar 31, 2019 | 989,001.58 |
| Dec 31, 2018 | 437,103.13 |
| Dec 31, 2015 | 375,917.90 |